AstraZeneca (NASDAQ:AZN) UP 0.62% AT 7944 Oxford Biomedica on Tuesday doubled the revenue expectation from its COVID-19 vaccine supply deal with AstraZeneca (NASDAQ:AZN) after the drug maker commissioned more batches from the company in the second half of 2021. Shares of the cell therapy firm, which has an agreement...